The effect of the 7-valent conjugate vaccine (PCV7) on the incidence of pneumococcal infections world-wide

Orsolya Dobay, Sebastian Gb Amyes, Károly Nagy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Streptococcus pneumoniae (pneumococcus) is responsible for the death of about 1 million children world-wide every year, causing community-acquired pneumonia, or invasive pneumococcal diseases. The highest disease burden is among young children or the elderly. The polysaccharide vaccine (Pneumovax, Merck) contains 23 capsular antigens, but this is ineffective in children less than 2 years old. Therefore a new vaccine was developed (Prevenar, Wyeth), in which seven capsular polysaccharides are conjugated to a carrier protein. Prevenar was first introduced in the USA in 2000 and later in several European countries. Many studies have considered the consequences of the vaccination with it. The major benefit is the general decrease in infections caused by the vaccine types, and because of herd immunity, also in unvaccinated children and adults. Conjugate vaccines are also able to reduce the nasopharyngeal carriage, which is a great problem with pneumococci. Additionally, the vaccine influenced pneumococcal resistance by the suppression of resistant clones. On the contrary, however, an increase in infections due to nonvaccine types has been detected everywhere. More worryingly, often a vaccine-induced serotype switch has been observed, that is the strains change their capsular type to a non-vaccine type, while retaining their genetic background, resistance or virulence.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalReviews in Medical Microbiology
Volume19
Issue number3
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Pneumococcal Infections
Conjugate Vaccines
Vaccines
Streptococcus pneumoniae
Pneumococcal Vaccines
Incidence
Polysaccharides
Herd Immunity
Infection
Virulence
Pneumonia
Carrier Proteins
Vaccination
Clone Cells
Antigens
Heptavalent Pneumococcal Conjugate Vaccine

Keywords

  • Pneumococcus
  • PVC-7
  • Replacement disease
  • Serotypes
  • Vaccination

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

The effect of the 7-valent conjugate vaccine (PCV7) on the incidence of pneumococcal infections world-wide. / Dobay, Orsolya; Amyes, Sebastian Gb; Nagy, Károly.

In: Reviews in Medical Microbiology, Vol. 19, No. 3, 07.2008, p. 79-85.

Research output: Contribution to journalArticle

@article{d19127ab4c3b47a4911428b9d0c64958,
title = "The effect of the 7-valent conjugate vaccine (PCV7) on the incidence of pneumococcal infections world-wide",
abstract = "Streptococcus pneumoniae (pneumococcus) is responsible for the death of about 1 million children world-wide every year, causing community-acquired pneumonia, or invasive pneumococcal diseases. The highest disease burden is among young children or the elderly. The polysaccharide vaccine (Pneumovax, Merck) contains 23 capsular antigens, but this is ineffective in children less than 2 years old. Therefore a new vaccine was developed (Prevenar, Wyeth), in which seven capsular polysaccharides are conjugated to a carrier protein. Prevenar was first introduced in the USA in 2000 and later in several European countries. Many studies have considered the consequences of the vaccination with it. The major benefit is the general decrease in infections caused by the vaccine types, and because of herd immunity, also in unvaccinated children and adults. Conjugate vaccines are also able to reduce the nasopharyngeal carriage, which is a great problem with pneumococci. Additionally, the vaccine influenced pneumococcal resistance by the suppression of resistant clones. On the contrary, however, an increase in infections due to nonvaccine types has been detected everywhere. More worryingly, often a vaccine-induced serotype switch has been observed, that is the strains change their capsular type to a non-vaccine type, while retaining their genetic background, resistance or virulence.",
keywords = "Pneumococcus, PVC-7, Replacement disease, Serotypes, Vaccination",
author = "Orsolya Dobay and Amyes, {Sebastian Gb} and K{\'a}roly Nagy",
year = "2008",
month = "7",
doi = "10.1097/MRM.0b013e3283299fa8",
language = "English",
volume = "19",
pages = "79--85",
journal = "Reviews in Medical Microbiology",
issn = "0954-139X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The effect of the 7-valent conjugate vaccine (PCV7) on the incidence of pneumococcal infections world-wide

AU - Dobay, Orsolya

AU - Amyes, Sebastian Gb

AU - Nagy, Károly

PY - 2008/7

Y1 - 2008/7

N2 - Streptococcus pneumoniae (pneumococcus) is responsible for the death of about 1 million children world-wide every year, causing community-acquired pneumonia, or invasive pneumococcal diseases. The highest disease burden is among young children or the elderly. The polysaccharide vaccine (Pneumovax, Merck) contains 23 capsular antigens, but this is ineffective in children less than 2 years old. Therefore a new vaccine was developed (Prevenar, Wyeth), in which seven capsular polysaccharides are conjugated to a carrier protein. Prevenar was first introduced in the USA in 2000 and later in several European countries. Many studies have considered the consequences of the vaccination with it. The major benefit is the general decrease in infections caused by the vaccine types, and because of herd immunity, also in unvaccinated children and adults. Conjugate vaccines are also able to reduce the nasopharyngeal carriage, which is a great problem with pneumococci. Additionally, the vaccine influenced pneumococcal resistance by the suppression of resistant clones. On the contrary, however, an increase in infections due to nonvaccine types has been detected everywhere. More worryingly, often a vaccine-induced serotype switch has been observed, that is the strains change their capsular type to a non-vaccine type, while retaining their genetic background, resistance or virulence.

AB - Streptococcus pneumoniae (pneumococcus) is responsible for the death of about 1 million children world-wide every year, causing community-acquired pneumonia, or invasive pneumococcal diseases. The highest disease burden is among young children or the elderly. The polysaccharide vaccine (Pneumovax, Merck) contains 23 capsular antigens, but this is ineffective in children less than 2 years old. Therefore a new vaccine was developed (Prevenar, Wyeth), in which seven capsular polysaccharides are conjugated to a carrier protein. Prevenar was first introduced in the USA in 2000 and later in several European countries. Many studies have considered the consequences of the vaccination with it. The major benefit is the general decrease in infections caused by the vaccine types, and because of herd immunity, also in unvaccinated children and adults. Conjugate vaccines are also able to reduce the nasopharyngeal carriage, which is a great problem with pneumococci. Additionally, the vaccine influenced pneumococcal resistance by the suppression of resistant clones. On the contrary, however, an increase in infections due to nonvaccine types has been detected everywhere. More worryingly, often a vaccine-induced serotype switch has been observed, that is the strains change their capsular type to a non-vaccine type, while retaining their genetic background, resistance or virulence.

KW - Pneumococcus

KW - PVC-7

KW - Replacement disease

KW - Serotypes

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=67649612798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649612798&partnerID=8YFLogxK

U2 - 10.1097/MRM.0b013e3283299fa8

DO - 10.1097/MRM.0b013e3283299fa8

M3 - Article

VL - 19

SP - 79

EP - 85

JO - Reviews in Medical Microbiology

JF - Reviews in Medical Microbiology

SN - 0954-139X

IS - 3

ER -